Dr Macleod has written a timely, comprehensive and humane article about the thorny issues of management in end-stage dementia.
Full article available to subscribers
Dr Macleod has written a timely, comprehensive and humane article about the thorny issues of management in end-stage dementia.1 But while the precise cause of the catastrophic brain failure that characterises late dementia may at that stage no longer be of direct relevance to management, I was nonetheless puzzled that Dr Macleod gave just passing reference to diagnosis and only mentioned Alzheimer’s disease, the most common cause, in his last paragraph.
As he states, dementia is a progressive, life-limiting syndrome. It is not a diagnosis in itself, but diagnosis is important. Occasionally, apparently profound dementia may have reversible causes such as hypothyroidism or severe, undiagnosed depressive disorder. Sometimes specific treatments may be indicated in the subtypes of neurodegenerative disorder that most commonly underly dementia. As they become better defined, it is increasingly likely that the associated genetic abnormalities will become of vital interest to relatives of sufferers. Precise diagnosis is also a necessary aspect of research.
In contemporary New Zealand practice, a diagnosis of the type of disorder causing dementia is usually made on clinical grounds by an experienced medical specialist, but not all patients see specialists. Psychometric testing is sometimes useful and imaging may provide a more definitive diagnosis, but both are constrained by the resources available. Postmortem brain examination is rarely done. The lack of a definitive diagnosis, supported by imaging or pathology, in many cases of dementia is regrettable, albeit that it may not contribute a great deal to the management of advanced cases.
John Turbott, MBChB, FRANZCP: Former Consultant Community Psychiatrist, St Lukes CMHC, Auckland District Health Care; Former Clinical Associate Professor, Department of Psychological Medicine, The University of Auckland.
Nil.
1) Macleod S. Dying with and of dementia. N Z Med J. 2024;137(1603):138-142. doi: 10.26635/6965.6683.
Sign in to view your account and access
the latest publications by the NZMJ.
Don't have an account?
Let's get started with creating an account.
Already have an account?
Become a member to enjoy unlimited digital access and support the ongoing publication of the New Zealand Medical Journal.
The New Zealand Medical Journal is fully available to individual subscribers and does not incur a subscription fee. This applies to both New Zealand and international subscribers. Institutions are encouraged to subscribe. The value of institutional subscriptions is essential to the NZMJ, as supporting a reputable medical journal demonstrates an institution’s commitment to academic excellence and professional development. By continuing to pay for a subscription, institutions signal their support for valuable medical research and contribute to the journal's continued success.
Please email us at nzmj@pmagroup.co.nz